Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Insight into p95 HER2 in Breast Cancer: Molecular Mechanisms and Targeted Therapies.
Publication

Publications

Insight into p95 HER2 in Breast Cancer: Molecular Mechanisms and Targeted Therapies.

Title
Insight into p95 HER2 in Breast Cancer: Molecular Mechanisms and Targeted Therapies.
Type
Article in International Scientific Journal
Year
2012
Authors
Ramon Andrade de Mello
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Alessandro de Vasconcelos
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Ronaldo A. Ribeiro
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Inês Pousa
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Noémia Afonso
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Deolinda Pereira
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Helena Rodrigues
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Vol. 6 No. 1
ISSN: 1872-2156
Publisher: Bentham Science
Indexing
Pubmed / Medline
Scientific classification
FOS: Medical and Health sciences > Basic medicine
Other information
Authenticus ID: P-008-2HN
Abstract (EN): Abstract: Breast cancer afflicts more than 1.3 million people worldwide and is the main cause of cancer-related deaths among women. Many efforts are underway to develop new therapeutic and biomarker strategies for the management of this disease. Hormone receptors and human epidermal growth factor receptor 2 (HER2) are currently the most important molecular tools in this regard. Moreover, targeted therapies including trastuzumab in particular are the primary treatment in both the adjuvant and recurrent settings. However, many studies reported that selected patients may present with resistance to trastuzumab due to the presence of p95HER2 fragments. To address this challenge, drugs such as lapatinib and others described in recent patents promise alternative therapeutic options. We discuss the most recent patents related to HER2 and p95HER2 fragments for breast cancer treatment.
Language: English
Type (Professor's evaluation): Scientific
Contact: ramonmello@med.up.pt
Documents
We could not find any documents associated to the publication.
Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-08-07 at 18:28:11 | Privacy Policy | Personal Data Protection Policy | Whistleblowing